Edwin Jonathan Tucker - 04 Jun 2025 Form 4 Insider Report for Jasper Therapeutics, Inc. (JSPR)

Reporting relationship: Chief Medical Officer
Issuer ticker: JSPR
Reported as of: 04 Jun 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 06 Jun 2025, 06:23:17 UTC
Prior SEC filing: 18 Feb 2025
Source filing: View source filing
Reporting owner signature: By: /s/ Herb Cross, as Attorney-in-Fact

Key filing fact

Edwin Jonathan Tucker filed Form 4 for Jasper Therapeutics, Inc. (JSPR) on 06 Jun 2025.

Key facts

This page summarizes Edwin Jonathan Tucker's Form 4 filing for Jasper Therapeutics, Inc. (JSPR).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 06 Jun 2025, 06:23.

Change

Previous filing in this sequence was filed on 18 Feb 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001792296 Primary reporting owner

Tucker Edwin Jonathan

Relationship: Chief Medical Officer
Address: C/O JASPER THERAPEUTICS, INC., 2200 BRIDGE PKWY, SUITE #102, REDWOOD CITY
Signature: By: /s/ Herb Cross, as Attorney-in-Fact
Signature date: 06 Jun 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

JSPR transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +90,000
Change %
Price: $0.000000
Shares after: 90,000
Date: 04 Jun 2025
Ownership: Direct
Underlying class: Voting Common Stock
Underlying amount: 90,000
Exercise price: $6.00
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

1/4th of the shares subject to the retention option shall vest on June 4, 2026 and 1/48th of the shares subject to the retention option shall vest following each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive.